Your Breakthrough Is Ready. Your Cap Table Isn't.
Take your lab-validated innovation cross-border — with the regulatory playbook, corporate structure, and investor introductions to actually close a round.
$50K
Non-Dilutive Grant
$250K
SAFE Syndicate Match
200+
Vetted Bio VCs
Delaware Flip & Cap Table Console
NeuroGen Bio Inc. · Cross-Border Entity
80/20 IP Transfer & 4-Year Reverse Vesting active.
$1.2M SAFE allocation locked at $8M valuation cap.
Delaware Flip Completed
Cross-border tax & legal compliance signed
Accelerator Pitch Batch #14
Applications close September 1st · Limited to 10 ventures
The Cross-Border Founder Dilemma
Why generic tech incubators fail deep-tech & healthcare founders with lab IP
Traditional Market Friction
Stuck in Regulatory & Cross-Border Cap Table Traps
You have lab-validated IP, maybe a provisional patent, but you're stuck navigating complex FDA pathways, Delaware C-Corp flips, and Western VC expectations with no cross-border precedent to follow.
Common Obstacles & Bottlenecks:
Messy Cap Tables
Complex local holding structures rejected by Western seed VC syndicates.
Regulatory Deadlocks
Overpaying for trial sites and FDA consulting without pre-sub guidance.
Cold Syndicate Outreach
Spending 6+ months emailing VCs who don't understand cross-border biotech.
Structured Operating System
Structured Path from Local Lab to Global Round
IGVP's Accelerator pairs you with seasoned founders who've already flipped entities and closed cross-border rounds, delivering regulatory playbooks and direct syndicate capital.
IGVP System Advantages:
Delaware Flip Support
Complete legal restructuring, 80/20 IP transfer, and Delaware C-Corp setup.
Clinical Trial Matching
Save 60% on trial costs with pre-vetted CDSCO CROs and hospital partners.
Syndicate Speed Dating
Direct pitch slots with 200+ bio angels and $250K SAFE match funding.
Execution Blueprint
From Lab IP to Closed Round in 90 Days
Delaware Flip Support
Complete corporate restructuring guidance and Delaware C-Corp flip support for cross-border IP.
Clinical Trial Matching
Cost-effective trial site matching with pre-vetted CRO and hospital partners across US & India.
Syndicate Pitch Slots
Direct pitch slots with the IGVP Syndicate and exclusive access to Speed-Dating cap table mixers.
MVP & Financial Sprints
Dedicated support from upskilling cohort teams to build financial models and pitch decks.
Role-Gated Discord & WhatsApp Communities
Self-segment upon entry into verified channels designed to accelerate co-founder matching, clinical trials, due diligence, and capital deployment.
Founder Verification Required
Checked against Accelerator application or provisional patent filing
🚀 Founders Category
Category Channels
Cross-Pollination Engine: Members collide across co-founder matching and deal-flow channels to fuel the Tri-Engine Flywheel.
Just submitted our FDA 510(k) Pre-Sub package! Special thanks to the #regulatory-fda team for reviewing our predicate device comparison table.
Looking for 2 more healthtech ventures with validated in-vitro data for our upcoming Thursday Speed-Dating mixer. Drop your memos in #healthtech-dealflow!
Scale Healthtech & Biotech Ventures Faster
Discover how healthtech founders leveraged IGVP's clinical network, FDA desk, and capital partners to raise, clear regulations, and deploy pilots.
"IGVP compressed five years of trial-and-error into one cohort. We closed our $14M Series A ninety days after Demo Day."
Dr. Priya Ravindran
Founder & CEO · NeuroGen Bio
$14M SERIES A
"The only place where I could pitch to a Kaiser CMO on Monday and an a16z partner on Wednesday — in one workspace."
Marcus Okafor, MD
Co-founder · Cardia Health
3 HOSPITAL LOIS
"We gained direct access to FDA regulatory advisors on IGVP who helped us navigate 510(k) clearance in record time."
Dr. Alex Chen
Founder & CTO · PulseMed Devices
FDA 510(K) CLEARED
"Using the Delaware flip package and legal office hours on IGVP, we structured cross-border entity flipped and secured $2.5M in seed SAFE checks."
Elena Vasquez
CEO · Omics Analytics
$2.5M SEED SAFE
"IGVP compressed five years of trial-and-error into one cohort. We closed our $14M Series A ninety days after Demo Day."
Dr. Priya Ravindran
Founder & CEO · NeuroGen Bio
$14M SERIES A
"The only place where I could pitch to a Kaiser CMO on Monday and an a16z partner on Wednesday — in one workspace."
Marcus Okafor, MD
Co-founder · Cardia Health
3 HOSPITAL LOIS
"We gained direct access to FDA regulatory advisors on IGVP who helped us navigate 510(k) clearance in record time."
Dr. Alex Chen
Founder & CTO · PulseMed Devices
FDA 510(K) CLEARED
"Using the Delaware flip package and legal office hours on IGVP, we structured cross-border entity flipped and secured $2.5M in seed SAFE checks."
Elena Vasquez
CEO · Omics Analytics
$2.5M SEED SAFE